Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AMR101 (ethyl-eicosapentaenoate) for severe hypertriglyceridemia
2009-010520-25Phase 3Completed
- Sponsor
- Amarin Corporation plc
- Start
- Jul 2009
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3-acid triglycerides in hypertriglyceridemia (3 arms), sponsored by Amarin Corporation plc. Primary endpoint: Percent change in triglycerides from baseline to Week 12 endpoint. Started Jul 2009; status: completed.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on 2009-010520-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010520-25.